<DOC>
	<DOC>NCT01841554</DOC>
	<brief_summary>To evaluate the performance and safety of the Cardioband Adjustable Annuloplasty System for repair of functional mitral regurgitation.</brief_summary>
	<brief_title>Cardioband With Transfemoral Delivery System</brief_title>
	<detailed_description />
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Age &gt; 18 years Moderate to severe functional MR Symptomatic Patients (NYHA ClassIIIV) despite optimal medical therapy , including CRT if indicated. LVEF ≥ 25%, LVEDD ≤ 65mm Subject is high risk to undergo MV surgery (as assessed by a surgeon and a cardiologist, at the site) Transseptal catheterization and femoral vein access is determined to be feasible Subject is able and willing to give informed consent and follow protocol procedures Active bacterial endocarditis Severe organic lesions with retracted chordae or congenital malformations with lack of valvular tissue Heavily calcified annulus or leaflets Subjects in whom transesophageal echocardiography is contraindicated Untreated clinically significant CAD requiring revascularization CRT implant within 3 months prior to procedure Any percutaneous coronary, carotid, endovascular intervention or carotid surgery within 30 days or any coronary or endovascular surgery within 3 months CVA or TIA within 6 months or severe carotid stenosis (&gt;70% by Ultra sound) Renal insufficiency requiring dialysis Life expectancy of less than twelve months Subject is participating in concomitant research studies of investigational products Mitral valve anatomy which may preclude proper device treatment Rightsided congestive heart failure with echocardiographic evidence of severe right ventricular dysfunction and severe tricuspid regurgitation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mitral Valve</keyword>
	<keyword>Annuloplasty</keyword>
</DOC>